Compare SFWL & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFWL | INCR |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 79.3M |
| IPO Year | 2023 | N/A |
| Metric | SFWL | INCR |
|---|---|---|
| Price | $1.00 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 90.8K | 39.7K |
| Earning Date | 08-27-2025 | 10-08-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.68 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $540,461,000.00 | $72,158,312.00 |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | $7.05 | ★ N/A |
| Revenue Growth | ★ 21.10 | N/A |
| 52 Week Low | $0.56 | $1.22 |
| 52 Week High | $1.29 | $1.79 |
| Indicator | SFWL | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 39.33 |
| Support Level | $0.56 | $1.35 |
| Resistance Level | $1.18 | $1.51 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 70.11 | 1.73 |
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.